Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

Noam Pondé, Dominique Agbor‑Tarh, Lissandra Dal Lago, Larissa A. Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D. Gelber, Aminah Jatoi, Amylou C. Dueck, Alvaro Moreno‑Aspitia, Christos Sotiriou, Evandro de Azambuja, Martine Piccart

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here. The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.

Original languageEnglish (US)
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)'. Together they form a unique fingerprint.

Cite this